Naber D - Search Results

1

Identification of increased genetic risk scores for schizophrenia in treatment-resistant patients.

Frank J, Lang M, Witt SH, Strohmaier J, Rujescu D, Cichon S, Degenhardt F, Nöthen MM, Collier DA, Ripke S, Naber D, Rietschel M. Frank J, et al. Among authors: naber d. Mol Psychiatry. 2015 Jul;20(7):913. doi: 10.1038/mp.2015.52. Epub 2015 Apr 14. Mol Psychiatry. 2015. PMID: 25869806 No abstract available.

2

Identification of increased genetic risk scores for schizophrenia in treatment-resistant patients.

Frank J, Lang M, Witt SH, Strohmaier J, Rujescu D, Cichon S, Degenhardt F, Nöthen MM, Collier DA, Ripke S, Naber D, Rietschel M. Frank J, et al. Among authors: naber d. Mol Psychiatry. 2015 Feb;20(2):150-1. doi: 10.1038/mp.2014.56. Epub 2014 Jun 3. Mol Psychiatry. 2015. PMID: 24888364 Free PMC article. No abstract available.

3

Efficacy and side-effects of clozapine not associated with variation in the 5-HT2C receptor.

Rietschel M, Naber D, Fimmers R, Möller HJ, Propping P, Nöthen MM. Rietschel M, et al. Among authors: naber d. Neuroreport. 1997 May 27;8(8):1999-2003. doi: 10.1097/00001756-199705260-00040. Neuroreport. 1997. PMID: 9223092 Clinical Trial.

4

Efficacy and side-effects of clozapine: testing for association with allelic variation in the dopamine D4 receptor gene.

Rietschel M, Naber D, Oberländer H, Holzbach R, Fimmers R, Eggermann K, Möller HJ, Propping P, Nöthen MM. Rietschel M, et al. Among authors: naber d. Neuropsychopharmacology. 1996 Nov;15(5):491-6. doi: 10.1016/S0893-133X(96)00090-5. Neuropsychopharmacology. 1996. PMID: 8914122 Clinical Trial.

5

Remitted but still impaired? Symptomatic versus functional remission in patients with schizophrenia.

Karow A, Moritz S, Lambert M, Schöttle D, Naber D; EGOFORS Initiative. Karow A, et al. Among authors: naber d. Eur Psychiatry. 2012 Aug;27(6):401-5. doi: 10.1016/j.eurpsy.2011.01.012. Epub 2011 May 12. Eur Psychiatry. 2012. PMID: 21570262

6

Remission as perceived by people with schizophrenia, family members and psychiatrists.

Karow A, Naber D, Lambert M, Moritz S; EGOFORS Initiative. Karow A, et al. Among authors: naber d. Eur Psychiatry. 2012 Aug;27(6):426-31. doi: 10.1016/j.eurpsy.2011.01.013. Epub 2011 May 14. Eur Psychiatry. 2012. PMID: 21571506

7

Clinical management of clozapine patients in relation to efficacy and side-effects.

Naber D, Holzbach R, Perro C, Hippius H. Naber D, et al. Br J Psychiatry Suppl. 1992 May;(17):54-9. Br J Psychiatry Suppl. 1992. PMID: 1358128

8

Efficacy and safety of an opiate sigma-receptor antagonist (SL 82.0715) in schizophrenic patients with negative symptoms: an open dose-range study.

Modell S, Naber D, Holzbach R. Modell S, et al. Among authors: naber d. Pharmacopsychiatry. 1996 Mar;29(2):63-6. doi: 10.1055/s-2007-979546. Pharmacopsychiatry. 1996. PMID: 8741023 Clinical Trial.

9

Improvement of schizophrenic patients' subjective well-being under atypical antipsychotic drugs.

Naber D, Moritz S, Lambert M, Pajonk FG, Holzbach R, Mass R, Andresen B. Naber D, et al. Schizophr Res. 2001 May 30;50(1-2):79-88. doi: 10.1016/s0920-9964(00)00166-3. Schizophr Res. 2001. PMID: 11378316 Clinical Trial.

10

[Open studies in comparison to controlled studies in testing of neuroleptics].

Pajonk FG, Holzbach R, Naber D. Pajonk FG, et al. Among authors: naber d. Fortschr Neurol Psychiatr. 2000 Jul;68(7):313-20. doi: 10.1055/s-2000-11638. Fortschr Neurol Psychiatr. 2000. PMID: 10945157 German.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

341 results

Search Page

Filters